MicroRNA-18a is elevated in prostate cancer and promotes tumorigenesis through suppressing STK4 in vitro and in vivo

Hsu, Tai-I; Hsu, Chao‐Yu; Lee, K. H.; Lin, Jen-Tai; Chen, Chang Shi; Chang, Kung Chao; Su, Cheng-Tau; Hsiao, Michael; Lu, Pei‐Jung

doi:10.1038/oncsis.2014.12

Cited by 102 publications

(98 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…miR-18a belongs to the miR17-92 gene cluster, of which HIF-1α is a target gene (16). It has been reported that miR-18a serves a crucial function in the occurrence and development of myocardial ischemia (17), colonic neoplasm (18), liver tumors (19), prostate cancer (20) and malignant gliomas (21). Furthermore, a previous study suggests that miR-18a may be a specific biomarker for the early diagnosis and treatment of tumors (22).…”

Section: Discussionmentioning

confidence: 99%

MicroRNA-18a regulates invasive meningiomas via hypoxia-inducible factor-1α

Gao

et al. 2015

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. The aim of the present study was to investigate the effects of microRNA-18a (miR-18a) on the invasiveness and metastasis of invasive meningiomas and the underlying mechanism. A total of 69 patients with meningiomas (30 patients in the invasive meningioma group and 39 patients in the non-invasive meningioma group) and 48 cases in the control group were enrolled. Samples of meningioma tissues, serum and cerebrospinal fluid were collected. Reverse transcription-quantitative polymerase chain reaction was performed to quantify the expression levels of hypoxia-inducible factor-1α (HIF-1α) mRNA and miR-18a. Western blot analysis was used to determine protein expression levels of HIF-1α. The expression levels of HIF-1α mRNA and protein in all three types of sample from the invasive meningioma group were significantly higher compared with those in the control and non-invasive meningioma groups (P<0.05), and the expression levels of HIF-1α mRNA in the serum and cerebrospinal fluid of the non-invasive meningioma group were significantly higher compared with those in the control group (P<0.05). The expression levels of miR-18a in the invasive meningioma group were significantly reduced compared with those in the control and non-invasive meningioma groups (P<0.05), whereas the levels of miR-18a in the non-invasive meningioma group were significantly lower compared with those in the control group (P<0.05). The expression of HIF-1α is significantly upregulated in patients with invasive meningiomas, possibly due to the downregulation of miR-18a expression. Therefore, miR-18a may regulate invasive meningiomas via HIF-1α.

show abstract

Section: Discussionmentioning

confidence: 99%

MicroRNA-18a regulates invasive meningiomas via hypoxia-inducible factor-1α

Gao

et al. 2015

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…The present study evaluated the levels of miR-18a, a highly expressed miRNA in the tissues of PC (16), in the peripheral blood of patients with PC or BPH, and in healthy individuals, to test the feasibility of using peripheral blood miR-18a as a potential novel non-invasive biomarker for PC.…”

Section: Discussionmentioning

confidence: 99%

“…In particular, miRNA (miR)-18a, which is located in the potentially oncogenic miR-17-92 cluster (12,13), is highly expressed in various types of cancer (13)(14)(15). Furthermore, miR-18a has recently been demonstrated to act as an oncogenic miRNA in PC by promoting tumorigenesis in in vitro and in vivo models of PC (16).…”

Section: Introductionmentioning

confidence: 99%

Increased oncogenic microRNA-18a expression in the peripheral blood of patients with prostate cancer: A potential novel non-invasive biomarker

2015

View full text Add to dashboard Cite

Abstract.MicroRNAs have been demonstrated to be stably detectable in peripheral blood, thus representing important sources of non-invasive biomarkers of various diseases, including cancer. Recently, microRNA-18a (miR-18a) has been revealed to be highly expressed in prostate cancer (PC) tissues, acting as an oncogenic miRNA. The present study evaluated miR-18a expression in the peripheral blood of patients with PC, patients with benign prostatic hyperplasia (BPH), and healthy individuals, to assess the feasibility of using peripheral blood miR-18a as a potential non-invasive biomarker for PC. Total RNA was extracted from peripheral whole blood samples from 24 PC patients, 24 BPH patients and 23 healthy control individuals. The expression of miR-18a was assessed by reverse transcription quantitative polymerase chain reaction. The results revealed that miR-18a expression was significantly higher in PC patients than in BPH patients and healthy controls [fold change (mean ± standard deviation), 5.5±1.4 for PC, 1.5±0.5 for BPH and 1.2±0.6 for controls; P<0.005]. Higher miR-18a expression was strongly associated with PC [odds ratio (OR), 4.602; 95% confidence interval (CI), 2.194-9.654; P=0.001], but was not significantly associated with BPH (OR, 1.2; 95% CI, 0.7-2.02; P=0.332). Despite the small number of patients, which limits the statistical power of the study, higher miR-18a expression was observed to be significantly correlated with certain clinicopathological parameters, including Gleason score >7 and pathological tumor stage 3/4 (P<0.005). A receiver operating characteristic (ROC) analysis revealed that miR-18a discriminated PC patients from BPH patients and healthy controls [area under the curve (AUC), 0.805; 95% CI, 0.704-0.906). Furthermore, use of the ROC curve to discriminate PC from BPH patients yielded an AUC of 0.878 (95% CI, 0.783-0.972). In summary, the present results indicate that miR-18a expression is significantly increased in peripheral blood of patients with PC compared with that of BPH patients and healthy individuals, and that higher miR-18a expression is associated with progression of PC. Peripheral blood oncogenic miR-18a may serve as a potential novel non-invasive biomarker for PC that also facilitates discrimination between PC and BPH.

show abstract

“…miRNA expression can be associated with a variety of cancer, either functioning as oncogene or tumor suppressor. miR-15a, 16-1,17-5p,143,145, and let-7 were identified as a tumor suppressor while miR-18a,19a-b, 20a,21,92,155, and 372 were known as oncomiRs [3,4]. Indeed, miRNA has showed potential value in cancer diagnosis and therapy.…”

Section: Introductionmentioning

confidence: 99%

PMMA Platform Based Micro Fluidic Mixer for the Detection of MicroRNA- 18a from Retinoblastoma Serum

Salim¹

2015

J Anal Bioanal Tech

View full text Add to dashboard Cite

MicroRNA-18a is elevated in prostate cancer and promotes tumorigenesis through suppressing STK4 in vitro and in vivo

Cited by 102 publications

References 43 publications

MicroRNA-18a regulates invasive meningiomas via hypoxia-inducible factor-1α

MicroRNA-18a regulates invasive meningiomas via hypoxia-inducible factor-1α

Increased oncogenic microRNA-18a expression in the peripheral blood of patients with prostate cancer: A potential novel non-invasive biomarker

PMMA Platform Based Micro Fluidic Mixer for the Detection of MicroRNA- 18a from Retinoblastoma Serum

Contact Info

Product

Resources

About